Drug Characteristics
  • Formulation

    Capsules: 30 mg, 45 mg, 75 mg, Suspension: 6 mg/mL

  • Dose

    Influenza A treatment I(AV)

    75 mg orally twice a day for 5 days followed by influenza vaccination

    Post-exposure prophylaxis

    75 mg orally once a day for 10 days

  • Side Effects

    Nausea, vomiting, abdominal pain, dyspepsia, diarrhoea; headache, fatigue, insomnia, dizziness; conjunctivitis, epistaxis; rash; very rarely hepatitis, Stevens–Johnson syndrome, and toxic epidermal necrolysis

  • Interactions

    Limited data.

    Low potential for drug interactions

  • Renal

    Dose in renal impairment GFR (ml/min) for treatment

    > 60 (ml/min) 75 mg twice daily

    > 30 to 60 (ml/min) 30 mg (suspension or capsules) twice daily

    > 10 to 30 (ml/min) 30 mg (suspension or capsules) once daily

    ≤ 10 (ml/min) Not recommended (no data available)

    Haemodialysis patients 30 mg after each haemodialysis session

    Peritoneal dialysis patients*30 mg (suspension or capsules) single dose

    Check SPC for prophylaxis

  • Hepatic

    No data on dosage reduction in patients with hepatic dysfunction

  • Pregnancy

    Compatible – Maternal Benefit >> Embryo-Foetal Risk

  • Other Information